RxDoctor Payments Data

Paolo Venegoni, MD

Interventional Cardiology · Austin, TXNPI 1790771814

Payments from drug & device makers

$14,699in general payments, 2019–2025

Across 603 payments — averaging $24.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$2K
  • Amgen$2K
  • Abiomed$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Novartis$718
  • plus $7K from 48 others

What the payments were for

  • Travel & lodging$2692%
  • Food & beverage$14,39098%
  • Education$390%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,699 in reported general payments places this provider in the 55th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$156,075
Medicare patients
809
Services billed
2,122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban164$169,044
Repatha SureclickEvolocumab113$111,854
EntrestoSacubitril/Valsartan80$83,663
XareltoRivaroxaban47$61,921
Droxidopa19$52,063
VascepaIcosapent Ethyl53$22,049
MultaqDronedarone Hcl17$19,032
FarxigaDapagliflozin Propanediol19$15,269
Repatha PushtronexEvolocumab15$12,047
EdarbiAzilsartan Medoxomil23$11,735
MounjaroTirzepatide11$10,940
JardianceEmpagliflozin14$10,704
Icosapent Ethyl19$7,754
Atorvastatin Calcium464$5,299
Metoprolol Succinate321$4,913

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$644$169,044164 claims
NovartisEntresto$718$83,66380 claims
Johnson & JohnsonXarelto$356$61,92147 claims
Sanofi-aventis U.S. LLCMultaq$160$19,03217 claims
AstraZenecaFarxiga$485$15,26919 claims
Arbor Pharmaceuticals, Inc.Edarbi$70$11,73523 claims
Lilly USA, LLCMounjaro$19$10,94011 claims
Boehringer IngelheimJardiance$504$10,70414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →